At the Coalition’s Rising Leaders conference on healthcare policy in Washington, D.C. May 22, a diverse set of speakers provided updates and predictions, and discussed the potential impact of the many significant healthcare policy decisions pending on Capitol Hill. This POV provides an overview of five issues to watch that were highlighted at the conference, as well as strategies for addressing them.
In the wake of the May 8 list-price mandate for DTC TV ads issued by the Centers for Medicare & Medicaid Services (CMS) -- and, even before that, since the draft rule was issued in October 2018 -- one of the questions we are hearing from clients is, “What about YouTube?” Read on to learn more.
On May 8, 2019, the Trump administration announced that the Centers for Medicare & Medicaid Services (CMS) would require drugs covered by Medicare or Medicaid to include a list price in any DTC television commercial within 60 days of the announcement, if their list price is at least $35 for a month’s supply or a course of treatment. The ruling is virtually the same as the one proposed in October 2018, and only products that advertise on TV are affected directly by the ruling. This POV provides a brief summary of the background to this ruling, a summary of its specifics, some reactions to it, and our recommendations to clients in its wake.
Wasn’t it exciting as a kid when one of your favorite TV shows would have a special multi-episode arc full of guest stars? Well, the same thing has been happening in the U.S. Senate this year, as the Finance Committee takes on drug pricing. They’ve held several hearings in which
Next week, Intouch's own Justin Chase, EVP of Innovation and Media, will participate in a panel discussion on the subject when the DTC National Conference convenes in Boston. Read on to learn more.
This POV, compiled and produced by the Intouch team who attended this year’s SXSW, brings all our insights about what pharma marketers need to keep in mind this year -- and beyond -- together in one place!
Each year, Intouch sleuths South by Southwest, talking to experts, sharing insights, and getting inspired by the most creative minds in the world. On the ground, we debrief, connect the dots, and distill our findings to the themes and actions that will mean most to our teams and clients.
The Finance Committee of the U.S. Senate held two hearings – one in January and one in February -- on “Drug Pricing in America: A Prescription for Change.” As we’ve seen them unfold, they’ve been reminders of ongoing tensions with the industry, and a harbinger of what may be on the horizon for pharma manufacturers.
Fake news is everywhere — not just in the political realm. Accuracy is more important than ever, particularly with respect to conveying health information. How is your brand handling the challenge?
TL;DR: Authenticity is a popular 21st-century marketing buzzword. But when you pick apart what’s really behind that, you find new opportunities for pharma marketers. Authenticity, transparency, humanity, vulnerability – there are a lot of ways to describe what the public increasingly wants from brands. But simply put: they want